Du lette etter:

pharmaceutics jcr

Pharmaceutics | An Open Access Journal from MDPI
https://www.mdpi.com/journal/pharmaceutics
Pharmaceutics | An Open Access Journal from MDPI Pharmaceutics Pharmaceutics is a peer-reviewed, open access journal on the science and technology of pharmaceutics and biopharmaceutics, and is published monthly online by MDPI.
Pharmaceutics- Impact Score, Overall Ranking, h-index, SJR ...
https://www.resurchify.com › details
Pharmaceutics is a journal covering the technologies/fields/categories related to Pharmaceutical Science (Q1). It is published by MDPI ...
Molecular Pharmaceutics - ACS Publications
https://pubs.acs.org › mpohbp
Recent highlights from the journal. antimicrobials illustration. Virtual Issues. Antimicrobials. This Virtual Issue features articles from various ACS journals ...
Pharmaceutics - Impact Factor, Overall Ranking, Rating, h ...
https://www.resurchify.com/impact/details/19700188360
16.11.2021 · Pharmaceutics is a journal covering the technologies/fields/categories related to Pharmaceutical Science (Q1). It is published by MDPI Multidisciplinary Digital Publishing Institute. The overall rank of Pharmaceutics is 4054 . According to SCImago Journal Rank (SJR), this journal is ranked 1.054.
Pharmaceutics - Scimago Journal & Country Rank
https://www.scimagojr.com › journ...
Pharmaceutics (ISSN 1999-4923) is an open access journal which provides an advanced forum for the science and technology of pharmaceutics and ...
Journal Impact Factor List 2021 – JCR, Web Of Science (PDF ...
https://impactfactorforjournal.com/jcr-2021
01.07.2021 · Impact Factor List of Journals For 2021 by JCR - CA-A CANCER JOURNAL FOR CLINICIANS - 508.7, Nature Reviews Molecular Cell Biology - 98.4, New
JCR Pharmaceuticals Co., Ltd. (4552.T) Stock Price, News ...
finance.yahoo.com › quote › 4552
JCR Pharmaceuticals Announces Approval of IZCARGO® (Pabinafusp Alfa) for Treatment of MPS II (Hunter Syndrome) in Japan JCR Pharmaceutical announced that the Ministry of Health, Labour and Welfare...
JCR Pharmaceuticals Co., Ltd.
www.jcrpharm.co.jp › en › site
JCR Pharmaceuticals Co., Ltd. Headquarters: 3-19 Kasuga-cho Ashiya, Hyogo, 659-0021 Japan: Representative: Shin Ashida Chairman and President: Founded: September 1975: Paid-in Capital: JPY 9,061million: Employees: 719 (As of March 31, 2021) Listed on: Tokyo Stock Exchange First Section (Securities code:4552) Scope of Business
Molecular Pharmaceutics Latest Impact Factor IF 2021-2022 ...
https://academic-accelerator.com/Impact-Factor-IF/Molecular-Pharmaceutics
09.01.2022 · The Molecular Pharmaceutics Latest Impact Factor IF 2021-2022 is 4.939. More Molecular Pharmaceutics Impact Factor Trend, Prediction, Ranking & …
JCR Pharmaceuticals : Notice of Transition to “Prime Market ...
www.marketscreener.com › quote › stock
1 day ago · JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceuticals company that is redefining expectations and expanding possibilities for people with rare and genetic diseases worldwide. We continue to build upon our 46-year legacy in Japan while expanding our global footprint into the US, Europe, and Latin America.
JCR Pharmaceuticals Co., Ltd.
www.jcrpharm.co.jp › en › site
This site uses cookies to improve your experience on the site. Please see our Cookie Policy for more information. By continuing to browse this site, you agree to the use of cookies.
JCR PHARMACEUTICALS CO., LTD. : 4552 Stock Price ...
www.marketscreener.com › quote › stock
Company. JCR Pharmaceuticals Co., Ltd. is a Japan-based company primarily engaged in the pharmaceutical business, as well as the medical and research equipment business. The Company operates in two segments. The Pharmaceutical segment engages in the research, production, purchase and sale of medical drugs and pharmaceutical raw materials.
Pharmaceutics | An Open Access Journal from MDPI
https://www.mdpi.com › journal
Pharmaceutics 2022, 14(1), 189; https://doi.org/10.3390/pharmaceutics14010189 (registering DOI) - 13 Jan 2022. Abstract. Over the last decade, ...
International Journal of Pharmaceutics | ScienceDirect.com ...
https://www.sciencedirect.com/journal/international-journal-of-pharmaceutics
International Journal of Pharmaceutics: X Metrics 2.7 weeks Time to First Decision The average number of weeks it takes for an article to go from manuscript submission to the initial decision on the article, including standard and desk rejects 5.1 weeks Review Time
JCR USA, Inc. - Biocom California
www.biocom.org › member › jcr-usa-inc
JCR USA, Inc. (JCR USA) is a joint venture company of two Japanese companies both of which are publicly listed on the Tokyo Stock Exchange. One of which is JCR Pharmaceutical Co., Ltd. (JCR) who owns 65% of JCR USA.
International Journal of Pharmaceutics
https://www.journals.elsevier.com › ...
International Journal of Pharmaceutics · The Impact Factor of this journal is 5.875, ranking it 37 out of 275 in Pharmacology & Pharmacy · With this journal ...
Pharmaceutics Latest Impact Factor IF 2021-2022 | Trend ...
https://academic-accelerator.com/Impact-Factor-IF/Pharmaceutics
31.12.2021 · Pharmaceutics The 2020-2021 Journal Impact IF of Pharmaceutics is 6.072, which is just updated in 2021. Pharmaceutics Journal Impact IF Highest IF 6.072 Key Factor Analysis Lowest IF 0.857 Key Factor Analysis Total Growth Rate 608.5% Key Factor Analysis Annual Growth Rate 60.9% Key Factor Analysis Pharmaceutics Journal Key Metrics Pharmaceutics
Pharmacology & Pharmaceutics | All Life - Taylor & Francis ...
https://think.taylorandfrancis.com › ...
Indexed in the Multidisciplinary Sciences JCR category and by EBSCOhost, Academic Search Complete, TOC Premier (Table of Contents), OCLC, Arts and Humanities ...
Pharmaceutics Latest Impact Factor IF 2021-2022 - Academic ...
https://academic-accelerator.com › ...
Pharmaceutics Latest Impact Factor IF 2021-2022 is 6.072. ... yearly starting from 1975 for journals listed in the Journal Citation Reports (JCR).
JCR Pharmaceuticals Announces Approval of IZCARGO ...
www.businesswire.com › news › home
Mar 23, 2021 · JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceuticals company that is redefining expectations and expanding possibilities for people with rare and genetic diseases...